Gene Editing Landscape: 187 Companies, 3 Focus Areas, and a $17B Market by 2028

Published on Spencer Knight via LinkedIn

Spencer Knight shares a compelling visual breakdown of 187 gene editing companies across four development stages—research, preclinical, clinical, and commercial—and three technical areas: genome, RNA, and epigenome editing. Sourced from William Blair’s market analysis, the report values the space at $8.76 billion today, with projected growth to $17.19 billion by 2028.

He poses a critical question: what factors will determine which companies make it? Scalability, delivery platforms, reimbursement models, and clinical proof will likely be key. Knight also predicts RNA editing companies will expand significantly in 2025.

Read the full post on LinkedIn:

👉 Spencer Knight: “Gene Editing Landscape 🚀”

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.